Related Experiment Video

Updated: May 20, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Programmed chemotherapy for patients with metastatic unresectable gastric cancer

Masataka Shinoda1, Takafumi Ando, Emad M El-Omar

  • 1Department of Gastroenterology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Plos One
|July 5, 2012
PubMed
Abstract

Insights

This study shows that a programmed chemotherapy approach improves survival for metastatic unresectable gastric cancer (MGC) patients. The regimen selection tool offers a promising strategy for personalized MGC treatment.

Area of Science:

  • Oncology
  • Clinical Pharmacology
  • Cancer Treatment

Background:

  • Metastatic unresectable gastric cancer (MGC) treatment faces challenges in selecting personalized regimens based on cancer subtype.
  • Recent advances include new drugs and combination therapies, but optimal selection remains difficult.
  • Programmed chemotherapy offers a potential solution for tailored MGC treatment strategies.

Observation:

  • Patients with MGC were stratified into three clinical condition groups.
  • A chemotherapy program utilizing S-1 combination regimens was implemented.
  • Median survival times (MST) varied by group: 416 days (Level 1), 208 days (Level 2), and 95 days (Level 3).

Findings:

  • The programmed chemotherapy approach demonstrated a 47% overall response rate in Level 1 patients.
  • Grade 3-4 toxicities, including neutropenia (12%) and anorexia (6%), were manageable and resolved without treatment-related deaths.
  • The program facilitated appropriate regimen selection, potentially enhancing patient survival.

Implications:

  • This programmed chemotherapy may serve as a novel clinical tool for efficient chemotherapy course selection in MGC.
  • It offers a structured approach to improve survival outcomes for patients with metastatic gastric cancer.
  • Further research incorporating new drugs and regimens can optimize the efficacy of this chemotherapy program.

More Related Videos

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

Single Incision Plus One Port Laparoscopic Proximal Gastrectomy with Double Channel Anastomosis for Gastric Cancer Treatment03:32

Single Incision Plus One Port Laparoscopic Proximal Gastrectomy with Double Channel Anastomosis for Gastric Cancer Treatment

Published on: December 27, 2024

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...